This book is written by frontline clinicians for clinicians in frontline clinical practice and researchers in the frontline of discovery. The 17 chapters cover all relevant topics in the field of plasma cell neoplasms and serve as a single source reference. The contents dive deep into the molecular basis for the pathophysiology of disease initiation, disease evolution, and the mechanisms of therapeutic actions. The authors provide a comprehensive review of risk stratification and staging processes incorporating tumor biology, host factors and therapeutic options. All currently approved therapeutic agents and regimens are compiled in a format that is easily grasped at a glance: individual drug pharmacology, regimen composition, dosing and schedule, clinical trial data on efficacy and relevant clinical toxicities. The role of stem cell transplantation in myeloma is analyzed in the greatest depth by the world authority on this topic. Further refinement of chimeric antigen receptor (CAR) T cell therapy in myeloma is reviewed by authors who have performed the most clinical and scientific work in the field. Practical management pearls from the precursor - MGUS to full-blown myeloma and plasma cell leukemia, from immunoglobulin chain deposition disease to paraneoplastic syndrome, from initial workup to long term surveillance are all in one place. The book, foreword by the world expert and closed by the real world practitioner in the field, lays the milestone of decades of trials and tribulations, captures the advances and achievements in conquering this affliction for many, and is a worthy collection.